Latest / Research To Practice | Oncology Videos
5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
Featuring an interview with Dr Seth Wander, including the following topics:
The clinical utility of ESR1 mutations in HR-positive, HER2-negative advanced breast cancer
Grinshpun A et al. The clinical utility of ESR1 mutations in hormone receptor-positive, HER2-negative advanced breast cancer. Hematol Oncol Clin North Am 2023;37(1):169-81. Abstract (0:00)
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy for ER-positive, HER2-negative advanced breast cancer
Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.